The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM
Abstract
BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II–III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy is efficacious and has a favorable safety profile, but limited evidence exists regarding monotherapy in real-world studies. This analysis aimed to describe the effectiveness and safety outcomes of mavacamten monotherapy in the real-world COLLIGO-HCM study (Mavacamten ObservationaL Evidence Global Consortium in Hypertrophic Cardiomyopathy). METHODS: Patient-level data recorded between April 2022 and February 2025 at 7 sites across 5 countries were extracted. Adult patients with a diagnosis of HCM from 2018 onwards were eligible for inclusion if they had ≥1 mavacamten prescription after the date of diagnosis. Patients were categorized based on background therapy status during mavacamten treatment: mavacamten monotherapy or mavacamten with background therapy (down-titration or no dose modification). RESULTS: Overall, 278 patients were included and received mavacamten (mavacamten monotherapy, n=88; mavacamten with background therapy, n=190). At month 9, most patients achieved ≥1 New York Heart Association class improvement from baseline (mavacamten monotherapy, 60.0%; mavacamten with background therapy, 61.0%). Improvements in resting and Valsalva left ventricular outflow tract gradients from baseline to month 9 were observed in both subgroups; mean left ventricular ejection fraction through month 9 remained ≥62.0% with mavacamten monotherapy and ≥61.4% with mavacamten with background therapy. Two patients in the mavacamten monotherapy subgroup and 1 patient in the mavacamten with background therapy subgroup permanently discontinued treatment owing to left ventricular ejection fraction <50%. CONCLUSIONS: Mavacamten monotherapy was associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over a 9-month follow-up period; this was consistent with improvements observed in patients treated with mavacamten with background therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06372457.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their success in obstructive HCM, myosin inhibitors failed to improve outcomes in the recent phase 3 ODYSSEY-HCM trial, underscoring the lack of effective therapies for nHCM [2,3].”
From Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy (2026) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citationOlivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31792-x · Cited by 1,296
Self-citationHypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
Maron, M. S., Olivotto, I., Zenovich, A. G., Link, M. S., Pandian, N. G., Kuvin, J. T., Nistri, S., Cecchi, F., Udelson, J. E., & Maron, B. J. (2006) · Circulation · doi:10.1161/circulationaha.106.644682 · Cited by 1,123
Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001250 · Cited by 807
Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.003 · Cited by 652
Anderson, R. L., Trivedi, D. V., Sarkar, S. S., Henze, M., Ma, W., Gong, H., Rogers, C. S., Gorham, J. M., Wong, F. L., Morck, M. M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809540115 · Cited by 405
Desai, M. Y., Owens, A., Geske, J. B., Wolski, K., Naidu, S. S., Smedira, N. G., Cremer, P. C., Schaff, H., McErlean, E., Sewell, C., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.04.048 · Cited by 376
Tian, Z., Li, L., Li, X., Wang, J., Zhang, Q., Li, Z., Peng, D., Yang, P. C., Ma, W., Wang, F., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3030 · Cited by 122
Self-citationLong-term effect of mavacamten in obstructive hypertrophic cardiomyopathy
Garcia-Pavia, P., Oręziak, A., Masri, A., Barriales-Villa, R., Abraham, T. P., Owens, A. T., Jensen, M. K., Wojakowski, W., Seidler, T., Hagege, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae579 · Cited by 114
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
García‐Pavía, P., Maron, M. S., Masri, A., Merkely, B. P., Nassif, M. E., Peña‐Peña, M. L., Villa, R. B., Bilen, O., Peña, M. S. B., Claggett, B. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504654 · Cited by 98
Self-citation
Cited by
Bal, H. S., Nayak, A., Pampana, A., Malay, S., Upadhyaya, A., Vekariya, N., Arora, G., & Arora, P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101451
Self-citation
Metadata
- Authors
- Bilen, O., Adler, A., Bastiaenen, R., MacNamara, J. P., Paratz, E., Maor, E., Arad, M., Gold, M., Patel, N., Pruett, C., Burford, E., Arora, G., Maksabedian Hernandez, E. J., Han, X., Schuler, P., Sandler, B., Li, L., Tian, D., Arora, P., & on behalf of the COLLIGO-HCM investigators
- Affiliations
- Department of Medicine, Emory University, Atlanta, GA (O.B., M.G.).
- University Health Network and Department of Medicine, Peter Munk Cardiac Centre, University of Toronto, Ontario, Canada (A.A.).
- Cardiology Department, Guy’s & St Thomas’ NHS Foundation Trust, London, United Kingdom (R.B., E.B.).
- University of Texas Southwestern Medical Center, Dallas (J.P.M., C.P.).
- The Alfred Hospital, Melbourne, Victoria, Australia (E.P.).
- Heart Failure Institute, Sheba Medical Center, Ramat Gan, Israel (E.M., M.A.).
- University of Alabama at Birmingham (N.P., G.A., P.A.).
- Bristol Myers Squibb, Princeton, NJ (E.J.M.H., X.H., P.S.).
- Bristol Myers Squibb, Uxbridge, United Kingdom (B.S.).
- IQVIA, Durham (L.L., D.T.).
- ORCID
- Venue
- Circulation: Genomic and Precision Medicine
- Published
- 2026-02
- Volume
- 19
- Issue
- 1
- ISSN
- 2574-8300
- PMC
- PMC12915557
- Cited by
- 5
- References
- 17
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Funders
- Bristol-Myers Squibb (N/A)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. https://app.cochat.ai/papers/10.1161/circgen.125.005502
- The paper
- Bilen, O., Adler, A., Bastiaenen, R., MacNamara, J. P., Paratz, E., Maor, E., Arad, M., Gold, M., Patel, N., Pruett, C., Burford, E., Arora, G., Maksabedian Hernandez, E. J., Han, X., Schuler, P., Sandler, B., Li, L., Tian, D., Arora, P., & on behalf of the COLLIGO-HCM investigators. (2026). Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.125.005502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.